A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

No serious adverse events occurred at dose levels 1-3, and no patients developed ICANS, a neuropsychiatric condition that can be a side effect of CAR T-cell therapy. Based on efficacy and safety ...

According to a post on X by sneaker-focused account Kicks Finder on Tuesday, the 19-year-old will have a special edition of the Nike G.T. Cut 3 Turbo LE, set to release on Aug. 1 for a projected ...

With its robust functionality and reliable tracking features, the Amazfit T-Rex 3 is a surprisingly formidable smartwatch, rivaling some premium Garmin or Apple models at a fraction of the price.

A study published in The Lancet Haematology has reported a 73% response rate for CAR T-cell therapy among patients ... countries are priced between USD 3,73,000 and 4,75,000.

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic ...

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free remission from autoimmune diseases observed after treatment ...

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent the longest reported remission to date in a patient treated with chimeric ...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. This time, the pharma is paying Xilio Therapeutics $52 million upfront to work on antibody-based ...

Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in blood cancers — with six CAR T-cell products now approved by the US Food and Drug Administration (FDA) to treat six ...

The same clone was detectable at a frequency of 0.01% of sequences on day 28 but was not detectable at any previous time point either before or after infusion (days 3 and 14 after CAR T-cell ...